Literature DB >> 11714193

Survival of macroencapsulated allogeneic parathyroid tissue one year after transplantation in nonimmunosuppressed humans.

A Tibell1, E Rafael, L Wennberg, J Nordenström, M Bergström, R L Geller, T Loudovaris, R C Johnson, J H Brauker, S Neuenfeldt, A Wernerson.   

Abstract

The use of immunoisolation devices may allow transplantation without need for immunosuppression and could widen the indications for cell transplantation. In this study, we evaluated the survival of encapsulated parathyroid tissue in nonimmunosuppressed humans. Autologous parathyroid implants: Seven patients undergoing parathyroidectomy had devices containing small pieces of their own parathyroid tissue implanted SC. These devices were explanted after 2-4 weeks for histological evaluation. Allogeneic parathyroid implants: Four patients with chronic hypoparathyroidism were transplanted with one to three large (40 microl) and one small (4.5 microl) device filled with meshed parathyroid tissue and implanted SC. The small devices were explanted at 4 weeks, while the large ones were explanted 8.5 to 14 months after implantation. In both studies, control implants were placed in nude mice. Autologous study results: At explantation, the grafts consisted of 22 +/- 6% endocrine tissue and 63 +/- 7% fibrosis, while 15 +/- 5% of the grafts were necrotic. Allogeneic study results: In devices explanted from the patients at 4 weeks, fibrosis dominated and only 1%, 5%, and 23% of the grafts consisted of endocrine tissue. A similar histological appearance was found in grafts from nude mice. In devices explanted at 8.5-14 months, histologically intact endocrine tissue was found in all patients. However, nearly all the tissue consisted of fibrosis. There was no detectable increase in the parathormone (PTH) level in all patients. Macroencapsulated human allogeneic parathyroid tissue can survive up to 1 year after transplantation into nonimmunosuppressed patients. However, marked fibroblast overgrowth occurred, especially in the allogeneic implant study, using meshed parathyroid tissue. This was probably not related to the allo-response, because similar findings were observed in the nude mouse implants. In future studies, better tissue preparation and improvements in the physiological milieu inside the device may help to reduce fibroblast overgrowth and increase survival of the parathyroid cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11714193

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  16 in total

Review 1.  Induction of tolerance to parental parathyroid grafts using allogeneic thymus tissue in patients with DiGeorge anomaly.

Authors:  Ivan K Chinn; M Louise Markert
Journal:  J Allergy Clin Immunol       Date:  2011-04-21       Impact factor: 10.793

Review 2.  Challenges and emerging technologies in the immunoisolation of cells and tissues.

Authors:  John T Wilson; Elliot L Chaikof
Journal:  Adv Drug Deliv Rev       Date:  2007-10-11       Impact factor: 15.470

Review 3.  Bioengineered sites for islet cell transplantation.

Authors:  Sophie Vériter; Pierre Gianello; Denis Dufrane
Journal:  Curr Diab Rep       Date:  2013-10       Impact factor: 4.810

Review 4.  Concise review: pancreas regeneration: recent advances and perspectives.

Authors:  Philippe A Lysy; Gordon C Weir; Susan Bonner-Weir
Journal:  Stem Cells Transl Med       Date:  2012-01-26       Impact factor: 6.940

Review 5.  Short and long-term impact of parathyroid autotransplantation on parathyroid function after total thyroidectomy.

Authors:  Gabrielle Hicks; Robert George; Mark Sywak
Journal:  Gland Surg       Date:  2017-12

6.  Synthesis of magnetic resonance-, X-ray- and ultrasound-visible alginate microcapsules for immunoisolation and noninvasive imaging of cellular therapeutics.

Authors:  Brad P Barnett; Aravind Arepally; Matthias Stuber; Dian R Arifin; Dara L Kraitchman; Jeff W M Bulte
Journal:  Nat Protoc       Date:  2011-07-14       Impact factor: 13.491

Review 7.  Progress and challenges in macroencapsulation approaches for type 1 diabetes (T1D) treatment: Cells, biomaterials, and devices.

Authors:  Shang Song; Shuvo Roy
Journal:  Biotechnol Bioeng       Date:  2016-01-04       Impact factor: 4.530

8.  Human beta-cell precursors mature into functional insulin-producing cells in an immunoisolation device: implications for diabetes cell therapies.

Authors:  Seung-Hee Lee; Ergeng Hao; Alexei Y Savinov; Ifat Geron; Alex Y Strongin; Pamela Itkin-Ansari
Journal:  Transplantation       Date:  2009-04-15       Impact factor: 4.939

9.  Sustained subcutaneous delivery of secretome of human cardiac stem cells promotes cardiac repair following myocardial infarction.

Authors:  Andrew R Kompa; David W Greening; Anne M Kong; Paul J McMillan; Haoyun Fang; Ritika Saxena; Raymond C B Wong; Jarmon G Lees; Priyadharshini Sivakumaran; Andrew E Newcomb; Bakhos A Tannous; Cameron Kos; Lina Mariana; Thomas Loudovaris; Derek J Hausenloy; Shiang Y Lim
Journal:  Cardiovasc Res       Date:  2021-02-22       Impact factor: 10.787

10.  Extracellular vesicles - mediating and delivering cardioprotection in acute myocardial infarction and heart failure.

Authors:  Aishwarya Prakash; Gustavo E Crespo-Avilan; Sauri Hernandez-Resendiz; Sang-Ging Ong; Derek J Hausenloy
Journal:  Cond Med       Date:  2020-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.